ArticleInvestigative ophthalmology & visual science2013
Low-intensity far-red light inhibits early lesions that contribute to diabetic retinopathy: in vivo and in vitro.
Article in Investigative ophthalmology & visual science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02457975 (Near-Infrared Photobiomodulation for the Treatment of Diabetic Macular Edema), which is not on this map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Near-Infrared Photobiomodulation for the Treatment of Diabetic Macular Edema
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- The Molecular Mechanisms of Action of Photobiomodulation Against Neurodegenerative Diseases: A Systematic Review.Cellular and molecular neurobiology · 2022Pooled it
- A Role for Photobiomodulation in the Prevention of Myocardial Ischemic Reperfusion Injury: A Systematic Review and Potential Molecular Mechanisms.Scientific reports · 2017Pooled it
- Repeated low-level red-light therapy for improving asthenopic symptoms and accommodation in presbyopia.Annals of medicine · 2026Trial
- Preclinical and clinical studies of photobiomodulation therapy for macular oedema.Diabetologia · 2020Trial
- A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION.Retina (Philadelphia, Pa.) · 2020Trial
- Near-Infrared and Red-Light Photobiomodulation for Ocular Aging and Diseases: A Narrative Review.Ophthalmology and therapy · 2026Review
- Potential Inhibitory Effect of LED-Sourced Red Light Therapy on Ocular Growth in Normal and Myopic Chicks.International journal of molecular sciences · 2026Article
- Profound Effect of Light on Cysts in X-Linked Retinoschisis.Investigative ophthalmology & visual science · 2026Article
- Photobiomodulation in animal models of ophthalmic disease: protocol for systematic review and meta-analysis of morphological, visual function, and inflammatory outcomes.Frontiers in medicine · 2026Article
- Roles of 670 nm Photobiomodulation on Rat Anterior Ischemic Optic Neuropathy: Enhancing RGC Survival, Mitochondrial Function, and Anti-Inflammatory Response.Antioxidants (Basel, Switzerland) · 2025Article
- Illuminating eye care: the promise and future of red light therapy in ophthalmology.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Review
- Photobiomodulation in ocular therapy: current status and future perspectives.International journal of ophthalmology · 2025Review
- Prolonged Photobiomodulation with Deep Red Light Mitigates Incipient Retinal Deterioration in a Mouse Model of Type 2 Diabetes.International journal of molecular sciences · 2024Article
- The Effect of Repeated Low-Level Red-Light Therapy on Myopia Control and Choroid.Translational vision science & technology · 2024Article
- Diabetes in spotlight: current knowledge and perspectives of photobiomodulation utilization.Frontiers in endocrinology · 2024Review
- Photobiomodulation use in ophthalmology - an overview of translational research from bench to bedside.Frontiers in ophthalmology · 2024Review
- Photobiomodulation Using Light-Emitting Diode (LED) for Treatment of Retinal Diseases.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- Smart Contact Lenses as Wearable Ophthalmic Devices for Disease Monitoring and Health Management.Chemical reviews · 2023Review
- Evaluation of Photobiomodulation and Boldine as Alternative Treatment Options in Two Diabetic Retinopathy Models.International journal of molecular sciences · 2023Article
- Considerations for the Use of Photobiomodulation in the Treatment of Retinal Diseases.Biomolecules · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
purposeTreatment with light in the far-red to near-infrared region of the spectrum (photobiomodulation [PBM]) has beneficial effects in tissue injury. We investigated the therapeutic efficacy of 670-nm PBM in rodent and cultured cell models of diabetic retinopathy.
methodsStudies were conducted in streptozotocin-induced diabetic rats and in cultured retinal cells. Diabetes-induced retinal abnormalities were assessed functionally, biochemically, and histologically in vivo and in vitro.
resultsWe observed beneficial effects of PBM on the neural and vascular elements of retina. Daily 670-nm PBM treatment (6 J/cm(2)) resulted in significant inhibition in the diabetes-induced death of retinal ganglion cells, as well as a 50% improvement of the ERG amplitude (photopic b wave responses) (both P < 0.01). To explore the mechanism for these beneficial effects, we examined physiologic and molecular changes related to cell survival, oxidative stress, and inflammation. PBM did not alter cytochrome oxidase activity in the retina or in cultured retinal cells. PBM inhibited diabetes-induced superoxide production and preserved MnSOD expression in vivo. Diabetes significantly increased both leukostasis and expression of ICAM-1, and PBM essentially prevented both of these abnormalities. In cultured retinal cells, 30-mM glucose exposure increased superoxide production, inflammatory biomarker expression, and cell death. PBM inhibited all of these abnormalities.
conclusionsPBM ameliorated lesions of diabetic retinopathy in vivo and reduced oxidative stress and cell death in vitro. PBM has been documented to have minimal risk. PBM is noninvasive, inexpensive, and easy to administer. We conclude that PBM is a simple adjunct therapy to attenuate the development of diabetic retinopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.